KR20180023057A - 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법 - Google Patents

배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법 Download PDF

Info

Publication number
KR20180023057A
KR20180023057A KR1020187005475A KR20187005475A KR20180023057A KR 20180023057 A KR20180023057 A KR 20180023057A KR 1020187005475 A KR1020187005475 A KR 1020187005475A KR 20187005475 A KR20187005475 A KR 20187005475A KR 20180023057 A KR20180023057 A KR 20180023057A
Authority
KR
South Korea
Prior art keywords
analgesic
pharmaceutical composition
agent
release
active ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187005475A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 에이. 딜
Original Assignee
웰즐리 파마슈티컬스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/343,349 external-priority patent/US20120141554A1/en
Priority claimed from US13/423,949 external-priority patent/US8236856B2/en
Priority claimed from US13/487,343 external-priority patent/US20120237574A1/en
Application filed by 웰즐리 파마슈티컬스 엘엘씨 filed Critical 웰즐리 파마슈티컬스 엘엘씨
Publication of KR20180023057A publication Critical patent/KR20180023057A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187005475A 2012-01-04 2012-08-22 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법 Ceased KR20180023057A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13/343,349 US20120141554A1 (en) 2010-07-08 2012-01-04 Delayed release formulation for reducing the frequency of urination and method of use thereof
US13/343,349 2012-01-04
US13/423,949 2012-03-19
US13/423,949 US8236856B2 (en) 2010-07-08 2012-03-19 Delayed release formulation for reducing the frequency of urination and method of use thereof
US13/487,343 US20120237574A1 (en) 2010-07-08 2012-06-04 Delayed-release formulation for reducing the frequency of urination and method of use thereof
US13/487,343 2012-06-04
PCT/US2012/051859 WO2013103389A1 (en) 2012-01-04 2012-08-22 Delayed-release formulation for reducing the frequency of urination and method of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147018674A Division KR20140108674A (ko) 2012-01-04 2012-08-22 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197012474A Division KR20190049928A (ko) 2012-01-04 2012-08-22 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법

Publications (1)

Publication Number Publication Date
KR20180023057A true KR20180023057A (ko) 2018-03-06

Family

ID=48745354

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187005475A Ceased KR20180023057A (ko) 2012-01-04 2012-08-22 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법
KR1020197012474A Ceased KR20190049928A (ko) 2012-01-04 2012-08-22 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법
KR1020147018674A Ceased KR20140108674A (ko) 2012-01-04 2012-08-22 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197012474A Ceased KR20190049928A (ko) 2012-01-04 2012-08-22 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법
KR1020147018674A Ceased KR20140108674A (ko) 2012-01-04 2012-08-22 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법

Country Status (12)

Country Link
US (2) US8703184B2 (enExample)
JP (3) JP2015506359A (enExample)
KR (3) KR20180023057A (enExample)
AU (1) AU2012363788B2 (enExample)
BR (1) BR112014016550A8 (enExample)
CA (1) CA2856673C (enExample)
IL (1) IL232711A0 (enExample)
MX (1) MX2014008284A (enExample)
RU (1) RU2597156C2 (enExample)
SG (1) SG11201500410XA (enExample)
WO (1) WO2013103389A1 (enExample)
ZA (1) ZA201403762B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10010514B2 (en) 2010-07-08 2018-07-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20130323288A1 (en) 2010-07-08 2013-12-05 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10105330B2 (en) * 2012-01-04 2018-10-23 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
US10278925B2 (en) * 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
US10792326B2 (en) 2013-06-28 2020-10-06 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
WO2016041036A1 (pt) * 2014-09-19 2016-03-24 Diffucap Chemobras Química E Farmacéutical Ltda Combinação farmacêutica contendo um agente analgésico e um agente antiespasmódico
JP2017516832A (ja) * 2014-06-06 2017-06-22 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための医薬製剤およびその使用の方法
US10105328B2 (en) * 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
KR20180054655A (ko) * 2015-09-01 2018-05-24 웰즐리 파마슈티컬스 엘엘씨 연장, 지연 및 즉시 방출 제형 제조 방법 및 용도
RU2018111401A (ru) * 2015-09-01 2019-10-02 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Составы с отсроченным высвобождением, способы их получения и применения
KR102314838B1 (ko) 2021-04-01 2021-10-19 송관권 터널 비개착공법
KR102364887B1 (ko) 2021-06-14 2022-02-18 송관권 터널 비개착 일체식 압입공법 및 그에 적용되는 일체식 가설구조물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050111784A (ko) * 2003-03-21 2005-11-28 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
KR20070027761A (ko) * 2004-08-20 2007-03-09 훼링 비.브이. 항이뇨제로서 유용한 헤테로사이클 축합 화합물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207940B (en) * 1989-02-16 1993-07-28 British Tech Group Feeder apparatus for controlled dissolution of the active components
DE122004000032I2 (de) * 1991-09-06 2006-02-09 Mcneilab Inc Zusammensetzung die eine Tramadol-Verbindung und Acetaminophen enth{lt, und ihre Verwendung
AU6747698A (en) * 1997-04-11 1998-11-11 Nippon Shinyaku Co. Ltd. Remedies for frequent urination and urinary incontinence
WO1999040942A1 (en) * 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
US7138393B2 (en) * 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
AU7360700A (en) 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
EP1313478A2 (en) 2000-08-30 2003-05-28 Lilly Icos LLC Method for treatment of migraine using pde5 inhibitors
RU2193401C1 (ru) * 2001-04-02 2002-11-27 Аль-Шукри Салман Хасунович Способ лечения гиперактивности мочевого пузыря
EP1437344A4 (en) 2001-09-28 2006-09-20 Takeda Pharmaceutical BENZENE DERIVATIVES AND PROCESS FOR THE PREPARATION AND USE THEREOF
AU2002354056A1 (en) * 2001-11-19 2003-06-10 Ono Pharmaceutical Co., Ltd. Remedies for urinary frequency
PL372395A1 (en) * 2002-02-19 2005-07-25 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
WO2004005309A2 (en) * 2002-07-08 2004-01-15 Pliva - Istrazivacki Institut D.O.O. Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
AU2003281044A1 (en) 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Pyrrolopyridine derivative and use thereof
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
WO2004026308A1 (en) * 2002-09-21 2004-04-01 Shuyi Zhang Sustained release compound of acetamidophenol and tramadol
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
DE10356112A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
EP1879578A4 (en) 2005-03-21 2009-05-13 Dov Pharmaceutical Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE
EP1741444A1 (en) * 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
US20080166407A1 (en) 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007072503A2 (en) * 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
WO2007083323A2 (en) 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
US20090069275A1 (en) 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
CA2569776A1 (en) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
US20070237816A1 (en) * 2006-04-06 2007-10-11 David Finkelstein Acetaminophen formulation for joint pain relief
AU2007276874B2 (en) 2006-07-28 2010-08-19 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
WO2008021625A2 (en) * 2006-08-18 2008-02-21 N.V. Organon Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
WO2009021007A1 (en) 2007-08-06 2009-02-12 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
US20120064159A1 (en) * 2009-05-28 2012-03-15 Aptapharma, Inc. Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120135050A1 (en) 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050111784A (ko) * 2003-03-21 2005-11-28 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
KR20070027761A (ko) * 2004-08-20 2007-03-09 훼링 비.브이. 항이뇨제로서 유용한 헤테로사이클 축합 화합물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BJU International, 97(4), 2006.4., pp.837-846 *
BJU International, 97(4), 2006.4., pp.837-846 1부. *

Also Published As

Publication number Publication date
IL232711A0 (en) 2014-07-31
KR20140108674A (ko) 2014-09-12
JP2017122091A (ja) 2017-07-13
ZA201403762B (en) 2015-10-28
BR112014016550A2 (pt) 2017-06-13
SG11201500410XA (en) 2015-04-29
BR112014016550A8 (pt) 2017-07-04
US8703184B2 (en) 2014-04-22
RU2597156C2 (ru) 2016-09-10
CA2856673A1 (en) 2013-07-11
WO2013103389A1 (en) 2013-07-11
US20140154314A1 (en) 2014-06-05
RU2014131238A (ru) 2016-02-20
US20130224291A1 (en) 2013-08-29
CA2856673C (en) 2018-08-21
JP2019055969A (ja) 2019-04-11
KR20190049928A (ko) 2019-05-09
JP2015506359A (ja) 2015-03-02
AU2012363788B2 (en) 2017-03-09
AU2012363788A1 (en) 2014-07-17
AU2012363788A2 (en) 2014-07-24
MX2014008284A (es) 2015-03-03
NZ626622A (en) 2016-11-25

Similar Documents

Publication Publication Date Title
KR20140108674A (ko) 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법
KR20140108675A (ko) 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법
US20120141554A1 (en) Delayed release formulation for reducing the frequency of urination and method of use thereof
KR20140134333A (ko) 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법
KR20150048741A (ko) 배뇨 빈도를 감소시키기 위한 약학적 조성물 및 이의 이용 방법
HK1249438A1 (zh) 用於缓解尿频的缓释制剂及其使用方法
US8236856B2 (en) Delayed release formulation for reducing the frequency of urination and method of use thereof
KR20180054655A (ko) 연장, 지연 및 즉시 방출 제형 제조 방법 및 용도
US8445011B2 (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof
US10278925B2 (en) Delayed-release formulations, methods of making and use thereof
EP2612662B1 (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof
TWI590822B (zh) 用於減少排尿頻率的延遲釋放製劑及其使用方法
EP2612661B1 (en) Delayed release formulation for reducing the frequency of urination and method of use thereof
KR20180054656A (ko) 지연-방출 제형, 제조 방법 및 용도
KR20180094512A (ko) 배뇨 빈도 감소용 조성물, 제조 방법 및 용도
KR20180066113A (ko) 배뇨 빈도 감소용 조성물, 제조 방법 및 용도
NZ626622B2 (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof
WO2013103356A1 (en) Delayed release formulation for reducing the frequency of urination and method of use thereof
TW201328724A (zh) 用於減少排尿頻率的延長釋放製劑及其使用方法

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180223

Application number text: 1020147018674

Filing date: 20140704

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180321

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180612

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180612

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190128

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180824

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180321

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190401

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190227

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190128

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180824

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180612

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180321

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190429

Application number text: 1020147018674

Filing date: 20140704